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The	purpose	of	 this	 study	was	 to	assess	 tactile	 learning	 in	 the	early	phase	of	experimental	
autoimmune	encephalomyelitis	(EAE),	which	was	induced	in	C57BL/6	mice	by	subcutaneous	
injections	on	flank	of	myelin	oligodendrocyte	glycoprotein,	MOG35-55	(250	µg	per	mouse).	
Tactile	learning	was	assessed	one	week	after	EAE	induction	using	the	novel	object	recognition	
test	 (NORT)	 in	 a	 dark	 room.	 The	 procedure	 consisted	 of	 two	 phases.	 During	 the	 training	
phase	 (T1),	 the	 animals	 explored	 two	 similar	 objects;	within	 the	 test	 phase	 (T2,	 occurring	 
4	h	later)	the	mice	explored	one	novel	and	one	familiar	object.	On	average,	mice	developed	
significant	behavioral	disabilities	related	to	EAE	13.2	±	1.9	days	following	immunization.	In	
the	EAE	group,	 the	 locomotor	activity	 level	(assessed	by	measuring	the	distance	 travelled)	
in	 the	T1	 and	T2	 phases	 did	 not	 differ	 significantly,	 as	 compared	 to	 the	 related	 phases	 in	
the	 control	 group	 (P >	 0.05).	Within	 phase	T1,	 no	 reliable	 differences	were	 found	 for	 the	
frequency	 (number)	 of	 visits	 to	 the	 sample	 objects	 and	 for	 total	 exploration	 time	 between	
experimental	groups.	For	phase	T2,	no	difference	was	also	found	in	the	discrimination	ratio	
when	comparing	the	control	group	with	the	EAE	group.	Our	study	demonstrates	that	tactile	
learning	in	male	mice	may	not	be	affected	7	days	after	immunization	with	MOG35-55	(i.e.,	
within	the	early	EAE	phase).
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INTRODUCTION
Multiple	 sclerosis	 (MS)	 is	 a	 progressive	
neurodegenerative	 disease	 of	 the	 CNS	 characterized	
by	 widespread	 lesions	 in	 the	 myelin	 sheaths	 of	 the	
fibers	 and	 damage	 to	 the	 gray	 matter	 [1].	 There	 is	
a	 great	 diversity	 of	 motor,	 somatosensory,	 visual,	
coordination,	 and	 cognitive	 symptoms	 and	 signs	 in	
MS	patients	[2].	The	attention	of	researches	has	only	
recently	 been	 focused	 on	 cognitive	 consequences	 in	
this	 disease.	A	 loss	 of	 learning	 and	memory	 abilities	
is	 the	 most	 common	 cognitive	 symptom	 evident	 in	 
40-65%	of	patients	suffering	from	MS	[3].	Certain	types	
of	memory	are	more	intensely	affected	in	this	disease.	
For	example,	it	was	reported	that	deficits	in	executive	
functions	 in	MS	 patients	 occurs	 less	 frequently	 than	
memory	or	processing	speed	disabilities	[4].
Experimental	 autoimmune	 encephalomyelit is	
(EAE)	is	one	of	the	most	used	models	for	studying	the	
etiopathogenesis	of	MS	[5].	Despite	being	traditionally	
concentrated	on	motor	dysfunction,	some	papers	have	
recently	 reported	 that	 there	 are	 behavioral	 changes	
in	EAE.	According	 to	Pollak	et	al.	 [6,	7],	 low	social	
interaction	and	low	sucrose	consumption	were	induced	
in	EAE	mice	when	compared	 to	 the	controls.	On	 the	
other	hand,	there	are	reports	demonstrating	that	spatial	
learning	 and	 recall	 (e.g.,	 in	 the	Morris	 water	 maze	
spatial	 memory	 test)	 were	 not	 impaired	 following	
induction	of	EAE	in	C57Bl/6	mice	[8].	
In	 our	 study,	we	 investigated	 tactile	 learning	 in	 a	
model	of	EAE	induced	in	C57BL/6	mice.
METHODS
Animals. The	 animals	 were	 purchased	 from	 the	
Rafsanjan	University	of	Medical	Sciences.	Mice	were	
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housed	in	groups	(two	to	four	per	cage)	and	maintained	
at	 a	 12	 h	 light/dark	 cycle	 (lights	 on	 07:00	 to	 19:00)	
with	free	access	to	food	and	water.	The	animal	housing	
temperature	was	maintained	at	23	±	2.0°C.	During	the	
experiments,	all	animals	were	weighed	every	day.	
Reagents. Myelin	 oligodendrocyte	 glycoprotein	
(MOG,	Alexis	Company,	USA)	along	with	complete	
Ferund’s	adjuvant	 (CFA),	Cresyl	Fast	Blue,	pertussis	
toxin,	Luxol	Fast	Blue,	and	lithium	carbonate	(Sigma-
Aldrich,	USA)	were	used	in	our	experiments.
Experimental Groups. Mice	were	randomly	divided	
into	three	experimental	groups	with	seven	mice	in	each	
group	 as	 follows:	 (i)	 control,	with	 no	 interventions,	
(ii)	 sham	group,	 in	which	animals	 received	CFA	and	
pertussis	 toxin	without	MOG,	 and	 (iii)	 EAE	 group,	
where	EAE	was	induced	using	MOG35-55,	CFA,	and	
pertussis	toxin.
Induction of EAE in Mice. EAE	was	induced	using	
a	peptide,	MOG35-55	 (Alexis,	USA),	corresponding	
to	 the	 sequence	 of	 rodent	MOG.	Experimental	mice	
received	a	subcutaneous	injection	on	flank	of	250	µg	
MOG35-55	per	mouse	emulsified	 in	CFA	containing	
0.4	 mg	 Mycobacterium  tuberculosis . 	 Animals	
also	 received	 pertussis	 toxin	 (500	 ng	 per	 mouse)	
immediately	after	 immunization	and	48	h	 later	 [10].	
In	the	sham-treated	group,	animals	received	CFA	and	
pertussis	 toxin	but	did	not	 receive	MOG.	Mice	were	
monitored	daily	for	weight	loss	and	neurological	signs	
of	EAE.	The	severity	of	the	disease	among	EAE	mice	
was	scored	based	on	the	method	reported	by	Onuki	et	
al.	[9,	10]:	grade	0,	no	signs	of	disease;	grade	1,	partial	
loss	of	tail	tonicity;	grade	2,	loss	of	tail	tonicity	along	
with	 tail	 righting	disabilities;	grade	3,	unsteady	gait	
and	mild	paralysis	of	one	hindlimb;	grade	4,	hindlimb	
paralysis	and	incontinence;	grade	5,	quadriplegia,	and	
grade	6,	the	animal	was	died.
Object Recognition Task. The	object	 recognition	
task	 assesses	 recognition	memory	 and	 is	 based	on	 a	
natural	 tendency	of	animals	 to	preferentially	explore	
novel	 objects,	 as	 opposed	 to	 familiar	 objects	 [11].	
The	 experimental	 apparatus	 was	 a	 Plexiglas	 box	 
(35×35×35	 cm)	with	 a	 black	 plastic	 floor	 placed	 in	
a	 dimly	 illuminated	 room	 [12].	 The	 objects	 to	 be	
discriminated	were	square	and	triangular	iron	blocks.	
The	behavior	of	 the	mice	was	 recorded	by	a	 camera	
positioned	 directly	 above	 the	 box	 and	 subsequently	
analyzed	 using	 Ethovison	 software	 (Noldus,	
Netherlands).
The	 object	 recognition	 task	 was	 done	 in	 three	
phases	 (habituation,	 training,	and	 test	phases)	with	a	
24-h-long	interval	between	the	habituation	and	training	
phases	and	4-h-long	interval	between	the	training	and	
test	 phases.	 During	 the	 habituation	 phase,	 the	mice	
were	allowed	to	freely	explore	the	box	in	the	absence	
of	 objects	 for	 30	 min.	 In	 the	 training	 phase	 (T1),	
each	 mouse	 was	 placed	 in	 the	 box	 with	 one	 object	
and	was	 allowed	 to	 explore	 for	 10	min.	 To	 prevent	
side	preference	affecting	the	results,	 the	position	and	
shape	 of	 the	 object	were	 changed	 after	 each	 animal	
was	 tested.	All	 mice	 were	 placed	 in	 the	 box	 at	 the	
same	point,	and	 they	were	 facing	 the	same	direction.	
Within	the	test	phase	(T2),	each	mouse	was	returned	to	
the	box	where	it	was	presented	with	a	familiar	object	
from	the	training	trial	(the	position	of	this	object	was	
consistent	between	both	training	and	test	phases)	and	
a	novel	object.	Exploration	 time	 in	phase	T2	was	10	
min	 (similar	 to	 that	 in	T1).	Care	was	 taken	 to	avoid	
olfactory	stimuli	by	cleaning	the	box	and	objects	with	
70%	ethanol	between	tests	[13].	The	time	spent	(sec)	
for	 exploring	 the	 objects	was	 recorded.	 Exploration	
was	 defined	 as	 pointing	 the	 nose	 to	 the	 object	 at	 a	
distance	≤2	cm.	Climbing	and/or	sitting	on	an	object	
were	 not	 considered	 as	 exploration.	 Within	 phase	
T2,	 the	 discrimination	 ratio	was	 calculated	 as	 (total	
time	 spent	 in	 exploring	 both	 objects	 divided	 by	 the	
time	 spent	 exploring	 novel	 objects	 only)	 ⋅	 100	 (%).	 
Mice	 showing	 a	 total	 exploration	 time	 <10	 sec	 on	
either	training	or	testing	phases	were	excluded	[13].
Statistical Analysis. Statistical	 analysis	 was	
performed	using	Excel	and	SPSS	softwares.	All	data	
are	expressed	as	means	±	s.e.m.	Differences	between	
the	groups	were	determined	using	ANOVA	followed	
by	the	Tukey	post-hoc	test.	The	paired	t-test	was	also	
used	 to	compare	activity	 levels	between	 the	 trial	and	
test	phases.	For	comparison	of	behavioral	scores	in	the	
EAE	group,	we	used	 repeated	measurement	ANOVA	
(RMA);	P	 values	 smaller	 than	0.05	were	 considered	
statistically	significant.
RESULTS
Behavioral Scores. In	 the	 EAE	 group,	 the	 first	
statistically	 significant	 behavioral	 scores	 of	 EAE	
became	 apparent,	 on	 averaged,	 13.2	 ±	 1.9	 days	 after	
immunization.	 In	 this	 group,	 the	 behavioral	 scores	
increased	 to	 a	 peak	 level	 of	 3.4	 ±	 0.8	 (17	 days	
following	 immunization;	 RMA,	 P	 =	 0.049).	 In	 the	
sham-treated	group,	we	observed	no	behavioral	scores	
of	EAE	throughout	the	period	of	study	(Fig.	1).
Body mass changes. The	mean	body	mass	of	mice	
in	 the	EAE	group	 on	 the	 21st	 day	was	 significantly	
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F i g. 1.	Means	 of	 behavioral	 scores	 of	mice	 in	 different	 groups.	
Abscissa)	 Days	 after	 immunization;	 ordinate)	 points.	 1	 and	 2)	
Scores	for	the	control	and	sham	groups;	3)	those	for	the	EAE	group.	
Р и с. 1.	Середні	величини	поведінкових	оцінок	(бали)	у	мишей	
різних	груп.
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F i g. 2.	Mean	 body	mass	 (g)	 of	mice	 in	 different	 groups	within	
the	observation	period.	Designation	of	the	groups	is	the	same	as	in	
Fig.	1.	Significant	difference	between	day	1	and	day	21	in	the	EAE	
group	(P	=	0.003)	is	shown	by	asterisk.
Р и с. 2.	 Середня	 маса	 тіла	 (г)	 мишей	 різних	 груп	 у	 межах	
спостережуваного	періоду.
TABLE 1. Frequencies and Times of Visits with Respect to Novel or Familiar Objects within Phases T1 and T2 in Three 
Experimental Groups
Частота та тривалість обстеження нових та раніше досліджених об’єктів у межах фаз Т1 та Т2 у мишей трьох 
експериментальних груп
Measured	index
Groups
control sham EAE
Trial	phase	(T1)
total	exploration	time,	sec 31.83	±7.1 38.24±9.2 50.74±2.06
number	of	visits	to	
both	objects	within	the	
observation	period
39.28±9.3 36.83±6.7 48.25±3.3
Test	phase	(T2)
time	to	visit	the	familiar	
object,	sec
21.24±5.2 25.5±5.6 22.32±6.5
time	to	visit	the	novel	
object,	sec	
20.07±5.06 29.19±5.4 32.87±5.2
total	exploration	time,	sec 41.32±10.1 54.69±10.0 48.62±12.9
number	of	visits	to	the	
familiar	object
27.85±6.7 31.6±8.2 29.6±8.0
number	of	visits	to	the	
novel	object
29.0±7.9 30.6±4.8 31.0±10.6
Footnotes.	Data	are	expressed	as	means	±	s.e.m.	The	T2	phase	was	done	24	h	after	T1.
lower	than	their	mean	mass	on	the	1st	day	(P	=	0.003).	
For	the	sham	and	control	groups,	we	did	not	observe	any	
body	mass	loss	throughout	the	study	(Fig.	2).
Novel Object Recognition Test: Activity Level. 
The	 activity	 level	 was	 assessed	 by	 measuring	 the	
distance	 travelled	 during	 the	 trial	 (T1)	 and	 test	
(T2)	phases	 (Fig.	3).	 In	 the	control	group,	 the	mean	
travelled	 distances	 in	 T1	 and	 T2	 did	 not	 differ	
significantly	 from	each	other	 (P	=	0.6).	 In	 the	 sham	
group,	 the	 travelled	distances	 in	T1	and	T2	were	not	
significantly	dissimilar	(P >	0.05).	In	the	EAE	group,	
the	travelled	distances	in	T1	and	T2	also	did	not	differ	
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Novel Object Recognition Test: Test Phase (T2). 
Object	exploration	times	during	the	test	phase	(T2)	in	
experimental	groups	are	shown	in	Table	1.	No	reliable	
differences	were	 found	 for	 the	 time	spent	 to	explore	
novel	and	 familiar	objects	between	 the	experimental	
groups	(all	P >	0.05).	The	mean	of	the	total	exploration	
time	of	both	objects	 (familiar	+	novel)	did	not	differ	
statistically	 from	each	other	 in	 the	 control	 and	EAE	
groups	 (P	>	0.05).	Moreover,	no	 reliable	differences	
were	 found	 for	 the	 frequency	 of	 visits	 to	 the	 novel	
and	 familiar	 objects	 between	 experimental	 groups	 
(all	P	>	0.05;	Table	1).	
A	 comparison	 of	 the	 discrimination	 ratio	 (Fig.	 4)	
between	 the	 experimental	 groups	 also	 revealed	 no	
difference	(P	=	0.3).
DISCUSSION
In	our	study,	we	were	unable	to	find	clear	impairment	
of	 tactile	 learning	 (assessed	 by	 the	 novel	 object	
recognition	 test)	 in	 C57BL/6	 male	 mice	 within	 the	
acute	phase	of	EAE.
Most	neurodegenerative	diseases,	like	Alzheimer’s,	
Parkinson’s,	 lateral	 sclerosis,	and	multiple	 sclerosis,	
exert	 deleterious	 effects	 on	 learning	 and	 memory,	
and	 these	 diseases	 mainly	 destroy	 integrative	 and	
cognitive	 abilities	 [14].	 Experimental	 autoimmune	
encephalomyelitis	 (EAE)	 is	 the	 most	 frequently	
studied	 animal	 model	 used	 for	 elucidation	 of	 the	
underlying	etiopathology	of	MS;	this	model	has	proved	
to	 be	 effective	 in	 the	 development	 of	 therapeutic	
strategy.	EAE	shares	many	clinical,	histopathological,	
and	 immunological	 features	 of	MS	 [15].	Nevertheless,	
there	are	some	differences	between	EAE	and	MS.	For	
example,	 in	EAE,	 the	CNS	area	primarily	affected	 is	
the	 spinal	 cord.	However,	 some	 recent	 studies	 have	
detected	 evidence	 of	 inflammation	 and	 neuronal	
changes	 in	 the	 brain	 of	 mice	 with	 EAE	 [16-19].	
Because	of	brain	dysfunction,	behavioral	disturbances	
in	animals	with	EAE	are	to	be	expected.	Thus,	recent	
studies	have	been	focused	on	cognitive	deficits	in	EAE	
to	find	the	possible	mechanisms	underlying	cognitive	
defects.
Recently,	Rodrigues	et	al.	[20]	checked	the	indices	
of	memory	and	anxiety	9	and	60	days	after	 induction	
of	 EAE	 with	 MOG35-55	 in	 C57Bl/6	 mice.	 They	
reported	no	differences	 in	memory	and	anxiety	when	
comparing	controls	and	animals	with	induced	EAE.	In	
addition,	Tu	et	 al.	 [8],	 reported	 that	 spatial	 learning	
and	 recall	 (in	 the	Morris	water	maze	spatial	memory	
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F i g. 3.	Locomotor	activity	level	in	the	control,	sham-treated,	and	
EAE	(1-3,	respectively)	groups.	The	activity	levels	were	measured	
according	 to	 the	 distance	 travelled	 within	 10	 min	 during	 both	
training	and	test	phases	(T1	and	T2,	respectively).	
Р и с. 3.	 Рівень	 локомоторної	 активності	 мишей	 різних	 груп	
(контрольних,	 псевдоін’єкованих	 та	 з	 експериментальним	
аутоімунним	енцефалітом,	1–3	відповідно).
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F i g. 4.	Mean	values	of	the	discrimination	ratio	in	different	experi-
mental	groups.	Designations	are	the	same	as	in	Fig.	3.
Р и с. 4.	Середні	величини	коефіцієнта	дискримінації	у	мишей	
різних	експериментальних	груп.
significantly	from	the	respective	values	in	the	control	
group	 (all	P >	 0.05).	Thus,	 the	 levels	 of	 locomotor	
activity	in	all	three	groups	demonstrated	no	significant	
differences	despite	 the	 fact	 that	 some	dissimilarities	
between	the	mean	estimates	were	noticeable	(Fig.	3).
Novel Object Recognition Test: Trial Phase (T1). 
The	total	time	spent	exploring	one	object	in	T1	(Table	
1)	was	not	statistically	different	in	the	control,	sham,	
and	 EAE	 groups	 (P	 >	 0.5).	 Similarly,	 no	 reliable	
differences	were	 found	between	experimental	groups	
for	the	frequency	(number)	of	visits	to	sample	objects	
(P	>	0.09;	Table	1).	Differences	between	 the	 indices	
measured	 varied	 somewhat	 but	 demonstrated	 no	
systematic	trends.
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test)	 were	 not	 affected	 following	 induction	 of	 EAE	
in	C57Bl/6	mice.	Our	 results	 also	demonstrated	 that	
tactile	 learning	 is	 not	 considerably	 impaired	 7	 days	
after	 induction	 of	 EAE	 in	 C57Bl/6	mice.	 Based	 on	
these	 results,	 one	 may	 conclude	 that	 learning	 and	
memory	 is	not	 affected	within	 the	early	EAE	phase.	
In	EAE,	 it	 is	well	 established	 that	T-cell	 infiltration	
and	 inflammation	 are	 the	 main	 cause	 of	 CNS	
demyelinating	 lesions	 and	 neurodegeneration	 [16].	
Therefore,	it	appears	possible	that	brain	inflammation	
should	 be	 associated	 with	 behavioral	 changes	 in	
EAE.	There	 are	 reports	 demonstrating	 little	 sign	 of	
inflammation,	T-cell	infiltration,	or	neurodegeneration	
in	 the	 brain	 of	 EAE	 mice	 within	 the	 early	 period	 
(7-10	 days	 after	 immunization	 with	 MOG35-55)	 
[16,	21].	Conversely,	 there	are	some	reports	showing	
noticeable	 behavioral	 changes	 in	EAE.	 Pollak	 et	 al.	 
[6,	7]	 reported	some	behavioral	 sickness	 in	 the	acute	
phase	of	EAE,	including	anorexia,	decreased	preference	
for	 sucrose	solution,	and	 reduced	social	exploration.	
It	 is	worth	mentioning	 that	 the	 cited	 authors	 used	 a	
dissimilar	EAE	model	induced	by	a	proteolipid	protein	 
in	SJL/J	mice.	
Although	most	studies	on	EAE	reported	that	clinical	
signs	of	EAE	would	start	9-14	days	post	immunization	
[22],	 there	 are,	 however,	 some	 communications	
reporting	 that	 clinical	 signs	 of	 EAE	 start	 sooner	
than	 7-14	 days	 post	 immunization	 [23,	 24].	 Hence,	
we	 tested	 animals	 for	 tactile	 learning	 (by	 the	 novel	
object	recognition	test,	NORT)	before	the	appearance	
of	EAE	clinical	signs	 (day	7	after	 immunization). As	
all	behavioral	 tests	depend	on	motor	function,	and	as	
it	seems	that	in	EAE	the	behavioral	changes	coincide	
with	the	severe	phase	of	the	disease	(within	this	phase,	
motor	 function	 is	 impaired),	 this	 imposes	a	 limit	 for	
evaluating	behavioral	changes	within	the	acute	phase	
of	 EAE.	 For	 example,	 Jones	 et	 al.	 [21]	 reported	
that	 numbers	 of	 crossings	 in	 the	 open	 field	 test	 are	
dissimilar	 in	 EAE	 and	 control	 animals.	However,	 it	
is	 not	 possible	 to	 conclude	whether	 this	 outcome	 is	
a	 result	 of	motor	 impairment	or	 if	 it	 is	 a	 behavioral	
change.	 Some	 investigators	 used	 a	 mild	 model	 of	
EAE	to	solve	 this	problem	based	on	 reduction	of	 the	
amount	 of	 pertussis	 toxin	 [25].	While	 this	 seems	 a	
good	strategy	 to	decrease	 the	motor	 impairment,	 the	
mechanisms	 that	 lead	 to	 the	behavioral	changes	may	
be	different.
Thus,	 the	 results	 of	 our	 study	 agree	 with	
observations	 reported	 in	 a	 few	 other	 studies	 and	
demonstrate	little	behavioral	changes	within	the	acute	
phase	of	EAE.		
Procedures	 involving	 animals	 and	 their	 care	 were	
conducted	 in	accordance	with	 the	Guide	 to	 the	Care	and	Use	
of	 Experimental	Animals	 (Olfert	 et	 al.,	 Canada,	 1993	 [26]).	
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Р	е	з	ю	м	е
Розвиток	 експериментального	 аутоімунного	 енцефало-
мієліту	 (ЕАЕ)	 викликали	 у	мишей	 за	 допомогою	 ін’єкцій	
мієлінового	олігодендроцитарного	глікопротеїну	 (MOG35-
55,	250	мкг	на	мишу).	Здатність	до	тактильного	навчання	
оцінювали	 через	 один	 тиждень	 після	 індукції	 ЕАЕ,	
використовуючи	тест	впізнавання	нового	об’єкта	(NORT)	у	
темному	приміщенні.	Процедура	 тестування	 складалася	 з	
двох	фаз;	протягом	першої	з	них	(T1)	тварини	обстежували	
два	однакових	об’єкта,	а	в	перебігу	другої	фази	(T2)	миші	
обстежували	один	новий	і	один	раніше	обстежений	об’єкти.	
Істотні	поведінкові	розлади,	зумовлені	ЕАЕ,	розвивались	у	
мишей	в	середньому	через	13.2	±	1.9	доби	після	імунізації.	
У	групі	ЕAЕ	рівень	локомоторної	активності	(оцінюваний	за	
відстанню,	котру	тварини	проходили	в	період	обстеження)	
в	межах	фаз	T1	 та	T2	 не	 відрізнявся	 істотно	 від	 такого	 в	
контрольній	групі	 (P >	0.05).	У	фазі	T1	не	спостерігалося	
істотних	міжгрупових	різниць	частоти	(кількості)	відвідань	
тест-об’єктів	 та	 загального	 часу,	 який	 було	 витрачено	 на	
ознайомлення	з	ними.	У	межах	фази	T2	не	виявлялося	також	
достовірних	різниць	величин	коефіцієнта	дискримінації	в	
контрольній	та	ЕAЕ-групах.	Отже,	наші	тести	показали,	що,	
видимо,	 тактильне	 навчання	 мишей-самцівне	 піддається	
істотним	змінам	через	 сім	діб	після	 імунізації	MOG35-55	
(тобто	в	межах	ранньої	фази	ЕAЕ).	
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